Metacrine Inc. (MTCR): Price and Financial Metrics


Metacrine Inc. (MTCR): $0.41

0.00 (0.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MTCR Stock Price Chart Interactive Chart >

Price chart for MTCR

MTCR Price/Volume Stats

Current price $0.41 52-week high $1.73
Prev. close $0.41 52-week low $0.30
Day low $0.40 Volume 36,000
Day high $0.41 Avg. volume 987,646
50-day MA $0.43 Dividend yield N/A
200-day MA $0.48 Market Cap 17.33M

Metacrine Inc. (MTCR) Company Bio


Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.


MTCR Latest News Stream


Event/Time News Detail
Loading, please wait...

MTCR Latest Social Stream


Loading social stream, please wait...

View Full MTCR Social Stream

Latest MTCR News From Around the Web

Below are the latest news stories about METACRINE INC that investors may wish to consider to help them evaluate MTCR as an investment opportunity.

Is Metacrine Inc. (MTCR) a opportunity to investors?

In Tuesday’s session, Metacrine Inc. (NASDAQ:MTCR) marked $0.46 per share, up from $0.42 in the previous session. While Metacrine Inc. has overperformed by 8.43%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MTCR fell by -63.85%, with highs and lows ranging from $1.73 to $0.30, whereas […]

US Post News | November 16, 2022

Metacrine Reports Third-Quarter 2022 Results

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progress during the quarter in advancing our proposed merger with Equillium,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “We believe that Equillium has demonstrated compelling clinical d

Yahoo | November 14, 2022

Can you still get a good price for Metacrine Inc. (MTCR) Shares at this point?

As of Tuesday, Metacrine Inc.’s (NASDAQ:MTCR) stock closed at $0.50, up from $0.42 the previous day. While Metacrine Inc. has overperformed by 18.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MTCR fell by -86.80%, with highs and lows ranging from $4.12 to $0.35, whereas the […]

US Post News | September 28, 2022

Why Is Equillium (EQ) Stock Soaring 20% Today?

Biotech firm Equillium is on the move as it released positive data for a lupus therapeutic, though EQ stock has a tough road ahead.

Josh Enomoto on InvestorPlace | September 27, 2022

Analysts Say That Metacrine Inc. (NASDAQ:MTCR) Is Likely To Make It To $0.50 In 12 Months

In last trading session, Metacrine Inc. (NASDAQ:MTCR) saw 0.36 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.43 trading at -$0.03 or -7.35% at ring of the bell on the day assigns it a market valuation of $18.80M. That closing price of MTCR’s stock is at … Analysts Say That Metacrine Inc. (NASDAQ:MTCR) Is Likely To Make It To $0.50 In 12 Months Read More »

Marketing Sentinel | September 24, 2022

Read More 'MTCR' Stories Here

MTCR Price Returns

1-mo 1.96%
3-mo -10.38%
6-mo -13.52%
1-year -68.22%
3-year N/A
5-year N/A
YTD -39.19%
2021 -91.42%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7448 seconds.